SEC Company Response from Neurogene Inc. (NGNE) (CIK 0001404644) (NGNE) — Mar 4, 2014
Neurogene Inc. (NGNE) (CIK 0001404644)
Date: March 4, 2014 · CIK: 0001404644 · Accession: 0001193125-14-082143
AI Filing Summary & Sentiment
File numbers found in text: 333-193615
Letter
March 4, 2014
Via E-mail and EDGAR Submission
United States Securities and Exchange Commission
Division of Corporation Finance
100 F. Street N.E.
Washington, DC 20549
Attention:
Jeffrey P. Riedler
Scot Foley
Bryan Pitko
Donald Abbott
Lisa Vanjoske
Re: Aquinox Pharmaceuticals, Inc.
Registration Statement on Form S-1 (Registration No. 333-193615)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, as the representatives of the prospective underwriters of the above issue, hereby join in the request of Aquinox Pharmaceuticals, Inc. that the effectiveness of the Registration Statement on Form S-1 (Registration No. 333-193615) be accelerated so that the Registration Statement will become effective by 3:00 p.m. Eastern Time on March 6, 2014, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act of 1933, as amended, and in connection with the foregoing, please note that we have effected between March 3, 2014 and the date hereof approximately the following distribution of the preliminary prospectus:
804 to institutions;
0 to prospective underwriters; and
10 to others.
The undersigned, as the representatives of the prospective underwriters of the above issue, hereby represent on behalf of the underwriters that the underwriters are acting in compliance and will act in compliance with the provisions of Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above proposed offering.
[Remainder of Page Intentionally Left Blank; Signature Page Follows]
Very truly yours,
JEFFERIES LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP March 4, 2014 Via E-mail and EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, DC 20549 Attention: Jeffrey P. Riedler Scot Foley Bryan Pitko Donald Abbott Lisa Vanjoske Re: Aquinox Pharmaceuticals, Inc. Registration Statement on Form S-1 (Registration No. 333-193615) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, as the representatives of the prospective underwriters of the above issue, hereby join in the request of Aquinox Pharmaceuticals, Inc. that the effectiveness of the Registration Statement on Form S-1 (Registration No. 333-193615) be accelerated so that the Registration Statement will become effective by 3:00 p.m. Eastern Time on March 6, 2014, or as soon thereafter as practicable. Pursuant to Rule 460 under the Securities Act of 1933, as amended, and in connection with the foregoing, please note that we have effected between March 3, 2014 and the date hereof approximately the following distribution of the preliminary prospectus: 804 to institutions; 0 to prospective underwriters; and 10 to others. The undersigned, as the representatives of the prospective underwriters of the above issue, hereby represent on behalf of the underwriters that the underwriters are acting in compliance and will act in compliance with the provisions of Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above proposed offering. [Remainder of Page Intentionally Left Blank; Signature Page Follows] Very truly yours, JEFFERIES LLC COWEN AND COMPANY, LLC By: JEFFERIES LLC By: /s/ Michael Brinkman Name: Michael Brinkman Title: Managing Director By: COWEN AND COMPANY, LLC By: /s/ James Barnes Name: James Barnes Title: Managing Director [Signature Page to Acceleration Request Letter]